TD Cowen raised the firm’s price target on McKesson (MCK) to $820 from $695 and keeps a Buy rating on the shares. The firm updated its estimates following Q4 results which assume no sale of the Med-Surg segment and includes contributions from FCS and PRISM Vision.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK:
- McKesson’s Strong Financial Outlook and Strategic Initiatives Lead to Buy Rating and Increased Price Target
- McKesson’s Earnings Call: Record Growth Amid Challenges
- McKesson price target raised to $800 from $755 at BofA
- McKesson’s Strategic Focus and Strong Financial Performance Justify Buy Rating
- McKesson’s Strategic Focus and Growth Potential: Buy Rating Affirmed